EUVIMEDEUVIMED entdecken
Crossref

Capivasertib — a new agent in the treatment algorithm for patients with advanced, metastatic HR-positive, HER2-negative breast cancer harboring genetic alterations in the PIK3CA/AKT1/PTEN genes

Tomasz Kubiatowski, Artur Kowalik, Roman Dubiański

Oncology in Clinical Practice · 15.01.2026 · 22

DOI: 10.5603/ocp.111079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology in Clinical Practice, online erschienen am 15.01.2026. Verfasst von Tomasz Kubiatowski und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Kubiatowski, T., Kowalik, A., & Dubiański, R. (2026). Capivasertib — a new agent in the treatment algorithm for patients with advanced, metastatic HR-positive, HER2-negative breast cancer harboring genetic alterations in the PIK3CA/AKT1/PTEN genes. Oncology in Clinical Practice, 22(0). https://doi.org/10.5603/ocp.111079

Vancouver

Kubiatowski T, Kowalik A, Dubiański R. Capivasertib — a new agent in the treatment algorithm for patients with advanced, metastatic HR-positive, HER2-negative breast cancer harboring genetic alterations in the PIK3CA/AKT1/PTEN genes. Oncology in Clinical Practice. 2026;22(0). doi:10.5603/ocp.111079

BibTeX
@article{Kubiatowski2026,
  author = {Kubiatowski, Tomasz and Kowalik, Artur and Dubiański, Roman},
  title = {Capivasertib — a new agent in the treatment algorithm for patients with advanced, metastatic HR-positive, HER2-negative breast cancer harboring genetic alterations in the PIK3CA/AKT1/PTEN genes},
  journal = {Oncology in Clinical Practice},
  year = {2026},
  volume = {22},
  number = {0},
  doi = {10.5603/ocp.111079}
}
Kostenlos starten →